Transcriptional changes in insulin- and lipid metabolism-related genes in the hippocampus of olfactory bulbectomized mice

Journal of Neuroscience Research

Volumn 86, Issue 14, 2008, Pages 3184-3193

  Gass, Peter ^a   Leonardi Essmann, Fernando ^a   Zueger, Maha ^a   Spanagel, Rainer ^a   Gebicke Haerter, Peter J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Affective disorders; Fatty acid binding protein; Insulin signalling; Molecular networks; Olfactory bulbectomy

Indexed keywords

FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 7; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; LIPID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DEPRESSION; GENE INTERACTION; GENE TARGETING; GENETIC TRANSCRIPTION; HIPPOCAMPUS; INSULIN METABOLISM; LIPID METABOLISM; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OLFACTORY BULBECTOMY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; AXOTOMY; DEPRESSION; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HIPPOCAMPUS; INSULIN; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; OLFACTORY BULB; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 54749132018     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21753     Document Type: Article

References (52)

1. Aijanseppa S, Kivinen P, Helkala EL, Kivela SL, Tuomilehto J, Nissinen A. 2002. Serum cholesterol and depressive symptoms in elderly Finnish men. Int J Geriatr Psychiatry 17:629-634.
2. Anthony TE, Mason HA, Gridley T, Fishell G, Heintz N. 2005. Brain lipid-binding protein is a direct target of Notch signaling in radial glial cells. Genes Dev 19:1028-1033.
3. Arai Y, Funatsu N, Numayama-Tsuruta K, Nomura T, Nakamura S, Osumi N. 2005. Role of Fabp7, a downstream gene of Pax6, in the maintenance of neuroepithelial cells during early embryonic development of the rat cortex. J Neurosci 25:9752-9761.
4. Bellizzi MJ, Lu SM, Masliah E, Gelbard HA. 2005. Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor. J Clin Invest 115:3185-3192.
5. Bennett E, Stenvers KL, Lund PK, Popko B. 1994. Cloning and characterization of a cDNA encoding a novel fatty acid binding protein from rat brain. J Neurochem 63:1616-1624.
6. Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, Tiret L, Ninio E. 2003. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 44:1381-1386.
7. Campo S, Sardo MA, Bitto A, Bonaiuto A, Trimarchi G, Bonaiuto M, Castaldo M, Saitta C, Cristadoro S, Saitta A. 2004. Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals. Clin Chem 50:2077-2082.
8. Carlsen J, De Olmos J, Heimer L. 1982. Tracing of two-neuron pathways in the olfactory system by the aid of transneuronal degeneration: projections to the amygdaloid body and hippocampal formation. J Comp Neurol 208:196-208.
9. Carnethon MR, Biggs ML, Barzilay JI, Smith NL, Vaccarino V, Bertoni AG, Arnold A, Siscovick D. 2007. Longitudinal association between depressive symptoms and incident type 2 diabetes mellitus in older adults: the cardiovascular health study. Arch Intern Med 167:802-807.
10. Chmurzynska A. 2006. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet 47:39-48.
11. Cryan JF, Holmes A. 2005. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4:775-790.
12. de la Monte SM, Xu XJ, Wands JR. 2005. Ethanol inhibits insulin expression and actions in the developing brain. Cell Mol Life Sci 62:1131-1145.
13. Duman RS, Heninger GR, Nestler EJ. 1997. A molecular and cellular theory of depression. Arch Gen Psychiatry 54:597-606.
14. Everson-Rose SA, Meyer PM, Powell LH, Pandey D, Torrens JI, Kravitz HM, Bromberger JT, Matthews KA. 2004. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabet Care 27:2856-2862.
15. Gavish M, Bachman I, Shoukrun R, Katz Y, Veenman L, Weisinger G, Weizman A. 1999. Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev 51:629-650.
16. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J. 2004. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80.
17. Gerstner JR, Vander Heyden WM, Lavaute TM, Landry CF. 2006. Profiles of novel diurnally regulated genes in mouse hypothalamus: expression analysis of the cysteine and histidine-rich domain-containing, zinc-binding protein 1, the fatty acid-binding protein 7 and the GTPase, ras-like family member 11b. Neuroscience 139:1435-1448.
18. Harkin A, Kelly JP, Leonard BE. 2003. A review of the relevance and validity of olfactory bulbectomy as a model of depression. Clin Neurosci Res 3:253-262.
19. Hartfuss E, Forster E, Bock HH, Hack MA, Leprince P, Luque JM, Herz J, Frotscher M, Gotz M. 2003. Reelin signaling directly affects radial glia morphology and biochemical maturation. Development 130:4597-4609.
20. Hellweg R, Zueger M, Fink K, Hortnagl H, Gass P. 2007. Olfactory bulbectomy in mice leads to increased BDNF levels and decreased serotonin turnover in depression-related brain areas. Neurobiol Dis 25:1-7.
21. Irizarry RA, Gautier L, Bolstad BM, Crispin M, et al. 2005. Affy: methods for Affymetrix oligonucleotide arrays. R package version 1.6.7.
22. Jaako-Movits K, Zharkovsky A. 2005. Impaired fear memory and decreased hippocampal neurogenesis following olfactory bulbectomy in rats. Eur J Neurosci 22:2871-2878.
23. Jaako-Movits K, Zharkovsky T, Pedersen M, Zharkovsky A. 2006. Decreased hippocampal neurogenesis following olfactory bulbectomy is reversed by repeated citalopram administration. Cell Mol Neurobiol 26:1559-1570.
24. Jesberger JA, Richardson JS. 1986. Effects of antidepressant drugs on the behavior of olfactory bulbectomized and sham-operated rats. Behav Neurosci 100:256-274.
25. Kelly JP, Leonard BE. 1994. The effect of tianeptine and sertraline in three animal models of depression. Neuropharmacology 33:1011-1016.
26. Kelly JP, Wrynn AS, Leonard BE. 1997. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 74:299-316.
27. Kopf D, Westphal S, Luley CW, Ritter S, Gilles M, Weber-Hamann B, Lederbogen F, Lehnert H, Henn FA, Heuser I, Deuschle M. 2004. Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J Clin Psychopharmacol 24:527-531.
28. Kurtz A, Zimmer A, Schnutgen F, Bruning G, Spener F, Muller T. 1994. The expression pattern of a novel gene encoding brain-fatty acid binding protein correlates with neuronal and glial cell development. Development 120:2637-2649.
29. Leonard BE, Tuite M. 1981. Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. Int Rev Neurobiol 22:251-286.
30. Licinio J, Wong ML. 2004. Translational research in psychiatry: pitfalls and opportunities for career development. Mol Psychiatry 9:117.
31. Lumia AR, Teicher MH, Salchli F, Ayers E, Possidente B. 1992. Olfactory bulbectomy as a model for agitated hyposerotonergic depression. Brain Res 587:181-185.
32. Meng S, Chen Z, Munoz-Antonia T, Wu J. 2005. Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor. Biochem J 391:143-151.
33. Nelms K, O'Neill TJ, Li S, Hubbard SR, Gustafson TA, Paul WE. 1999. Alternative splicing, gene localization, and binding of SH2-B to the insulin receptor kinase domain. Mamm Genome 10:1160-1167.
34. Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK, Hen R, Koester S, Lederhendler I, Meaney M, Robbins T, Winsky L, Zalcman S. 2002. Preclinical models: status of basic research in depression. Biol Psychiatry 52:503-528.
35. Owada Y, Abdelwahab SA, Kitanaka N, Sakagami H, Takano H, Sugitani Y, Sugawara M, Kawashima H, Kiso Y, Mobarakeh JI, Yanai K, Kaneko K, Sasaki H, Kato H, Saino-Saito S, Matsumoto N, Akaike N, Noda T, Kondo H. 2006. Altered emotional behavioral responses in mice lacking brain-type fatty acid-binding protein gene. Eur J Neurosci 24:175-187.
36. Pelsers MM, Glatz JF. 2005. Detection of brain injury by fatty acid-binding proteins. Clin Chem Lab Med 43:802-809.
37. Pelsers MM, Hanhoff T, Van der Voort D, Arts B, Peters M, Ponds R, Honig A, Rudzinski W, Spener F, de Kruijk JR, Twijnstra A, Hermens WT, Menheere PP, Glatz JF. 2004. Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin Chem 50:1568-1575.
38. Pocklington AJ, Cumiskey M, Armstrong JD, Grant SG. 2006. The proteomes of neurotransmitter receptor complexes form modular networks with distributed functionality underlying plasticity and behaviour. Mol Syst Biol 2:23 [E-pub Jan 17].
39. Possidente B, Lumia AR, McGinnis MY, Rapp M, McEldowney S. 1996. Effects of .uoxetine and olfactory bulbectomy on mouse circadian activity rhythms. Brain Res 713:108-113.
40. R Development Core Team. 2005. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. ISBN 3-900051-07-0; http://www.R-project.org.
41. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P, Warot XM, Rio C, Corfas G, White MF. 2003. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 23:7084-7092.
42. Song C, Leonard BE. 1994. The effects of chronic lithium chloride administration on some behavioral and immunological changes in the bilaterally olfactory bulbectomized rat. J Psychopharmacol 8:440-447.
43. Song C, Leonard BE. 1995. Interleukin-2-induced changes in behavioral, neurotransmitter, and immunological parameters in the olfactory bulbectomized rat. Neuroimmunomodulation 2:263-273.
44. Song C, Leonard BE. 2005. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29:627-647.
45. Taniguchi CM, Ueki K, Kahn R. 2005. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 115:718-727.
46. van Riezen H, Leonard BE. 1999. Acts of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. Pharmacol Ther 47:21-34.
47. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034.
48. Weber-Hamann B, Gilles M, Lederbogen F, Heuser I, Deuschle M. 2006. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 67:1856-1861.
49. Willner P. 1990. Animal models of depression: an overview. Pharmacol Ther 45:425-455.
50. Wrynn AS, Mac Sweeney CP, Franconi F, Lemaire L, Pouliquen D, Herlidou S, Leonard BE, Gandon J, de Certaines JD. 2000. An in-vivo magnetic resonance imaging study of the olfactory bulbectomized rat model of depression. Brain Res 879:193-199.
51. Xu J, Yeon JE, Chang H, Tison G, Chen GJ, Wands J, de la Monte S. 2003. Ethanol impairs insulin-stimulated neuronal survival in the developing brain: role of PTEN phosphatase. J Biol Chem 278:26929-26937.
52. Zueger M, Urani A, Chourbaji S, Zacher C, Roche M, Harkin A, Gass P. 2005. Olfactory bulbectomy in mice induces alterations in exploratory behavior. Neurosci Lett 374:142-146.